How Much Does Entresto Cost in 2026?

Entresto (sacubitril and valsartan) is a twice-daily tablet for chronic heart failure. Medicare negotiated $295 for a 30-day supply, 53% below the $628 list price, effective January 1, 2026. Two things make this the odd one out in the program. Generic sacubitril and valsartan has been on US pharmacy shelves since July 2025, and because of that competition CMS is removing Entresto from the negotiation program on January 1, 2027.

  • Medicare's negotiated price is $295 per 30-day supply for 2026 only. Entresto exits the negotiation program on January 1, 2027, after which your plan sets the price the ordinary way again.
  • Generic sacubitril and valsartan is already available, first marketed July 22, 2025, with several more manufacturers approved through 2026. It entered at a steep discount to the brand.
  • For most people the generic, not the negotiated price, is the answer. Ask your pharmacist what the generic costs on your plan before you assume $295 is your benchmark.
  • The generic covers Entresto tablets. There is no generic for Entresto Sprinkle capsules, used mainly in pediatric patients.

What You Actually Pay

Figures are for a 30-day supply. List and negotiated prices are from CMS; what you pay depends on your coverage.

Your situationTypical cost
Medicare negotiated price, 2026$295 / 30 days
Medicare Part D, your shareup to $2,100 / year
Commercial insurancecopay or coinsurance
Uninsured, cash~$628 (list)

Why Entresto Is Leaving the Program, and What That Means for You

A drug can only be selected for Medicare negotiation if it faces no bona fide generic or biosimilar competition. Entresto qualified when it was picked. Then a key patent lapsed, generics launched in July 2025, and CMS determined that real competition now exists. The result is that Entresto, along with Stelara and Xarelto, stops being a selected drug on January 1, 2027.

So the $295 negotiated price is a one-year price. That sounds alarming and mostly is not, because the thing replacing it is generic competition, which historically pushes prices well below any negotiated figure. What it does mean is that you should not plan around $295 as a durable number, and you should not treat it as the cheapest available option in 2026 either. The generic is very likely cheaper than the brand at the negotiated price right now.

What Medicare's Negotiated Price Does, and Does Not, Change

The headline number is not your copay.

$295 is the maximum fair price, the amount Medicare and your Part D plan pay for a 30-day supply of Entresto. What you are charged at the counter is still set by your plan's tier and cost-sharing rules.

It helps you directly if you pay coinsurance

Many plans charge a percentage of the drug's price on brand and specialty tiers. If you owe 25% of $628, that is far more than 25% of $295. When your share is a percentage, a lower negotiated price lowers your bill directly.

It may not change a flat copay

If your plan charges a fixed dollar copay for that tier, your copay can stay the same even though the plan is paying less. The benefit then shows up in the program's overall costs rather than your receipt.

It changes how fast you hit the cap

Your spending counts toward the $2,100 annual Part D out-of-pocket cap in 2026. A cheaper drug means a smaller share each month, which can mean you reach the cap later or not at all, so the year-end picture differs from past years.

It does not change coverage rules

A negotiated price does not force a plan to cover Entresto, drop prior authorization, or change its tier. Plans still set their own formularies, so check yours before you assume the new price applies to you.

Because tiers and cost-sharing vary so much between plans, the only way to know your real cost is to check Entresto against each plan's formulary. If you would rather have that done for you, our Find My Medicare Plan service checks your specific drugs against the plans available to you for a flat $99.

Is There a Generic for Entresto?

Yes, and that is the most useful fact on this page. Generic sacubitril and valsartan tablets reached US pharmacies on July 22, 2025, and several additional manufacturers have been approved since, which normally drives the price down further. Entresto Sprinkle capsules have no generic. Because generic competition now exists, CMS is removing Entresto from the Medicare negotiation program effective January 1, 2027.

Does Insurance Cover Entresto?

Usually, with conditions

Entresto is covered by Medicare Part D and most commercial plans, and heart failure guidelines place it as a first-line therapy, so coverage is rarely the problem. Now that a generic exists, expect plans to prefer it and to apply step therapy or a higher tier to the brand. If you are doing well on the brand and your plan moves it, that is appealable, though in this case the generic is the same two active ingredients.

If you are denied or moved a tier

A denial is not the end, and a tier change at renewal is not either. Your prescriber can submit a letter of medical necessity or a formulary exception, and you have formal appeal rights. See how to appeal an insurance denial and what to do when a plan drops your drug.

How to Pay Less

Ask for the generic by name

Generic sacubitril and valsartan is an AB-rated substitute for Entresto tablets, so in most states your pharmacist can substitute it unless the prescription says otherwise. Ask what it costs on your plan and as a cash price, because on a newly genericized drug the cash price sometimes beats the insured copay.

Do not stop or change dose on your own

Entresto is a heart failure medication and the dose is titrated deliberately. Switching brand to generic is a pricing change, not a treatment change, but stopping or skipping to save money is a clinical risk. Raise cost with your prescriber instead.

On Medicare, check Extra Help and the payment plan

Extra Help (the Low Income Subsidy) sharply reduces Part D costs and its income limits are higher than most people expect. The Medicare Prescription Payment Plan can also spread your Part D costs evenly across the year instead of front-loading them, and you opt in through your plan.

Check the tier before you commit to a plan

The same drug can cost very different amounts across plans in the same ZIP code. During open enrollment, compare Entresto on each plan's formulary, and remember the plan that was cheapest last year may not be this year.

Push back on a bill you have already received

If you were billed more than you expected, or a claim was processed wrong, CareRoute Bill Defense reviews and disputes medical bills, with no fee unless we save you money.

Not sure which plan covers Entresto best?

For a flat $99, we research the Medicare plans available to you and check them against your specific drugs and doctors, then hand you a clear comparison. We are independent, sell no insurance, and take no commissions.

Frequently Asked Questions

Is there a generic for Entresto?

Yes. Generic sacubitril and valsartan tablets have been sold in US pharmacies since July 22, 2025, and more manufacturers have received FDA approval through 2026, which usually pushes prices down further. The generic is AB-rated, meaning your pharmacist can normally substitute it for the brand. There is no generic for Entresto Sprinkle capsules. Because this competition now exists, CMS is removing Entresto from the Medicare negotiation program on January 1, 2027.

Why is Entresto leaving the Medicare negotiation program?

Medicare can only negotiate the price of a drug that has no bona fide generic or biosimilar competition. Entresto met that test when it was selected, but generics launched in July 2025, so CMS determined competition now exists and Entresto stops being a selected drug on January 1, 2027. Stelara and Xarelto are leaving for the same reason on the same date. The $295 negotiated price applies for 2026 only, after which your plan negotiates with the manufacturer the ordinary way. In practice the generic is likely to be cheaper than either figure.

What is Medicare's negotiated price for Entresto?

Medicare negotiated a maximum fair price of $295 for a 30-day supply of Entresto, effective January 1, 2026. That is 53% below the $628 list price CMS used as the comparison. Entresto was one of the first ten drugs in the Medicare Drug Price Negotiation Program, selected because it was among the highest-spending Part D drugs without generic or biosimilar competition at the time. The price applies automatically at the pharmacy for Part D members.

Will the negotiated price lower what I actually pay for Entresto?

It can, but it is not your new copay. The maximum fair price is what Medicare and your Part D plan pay the pharmacy, not automatically what you are charged. If your plan charges coinsurance, a percentage of the drug price, a lower negotiated price lowers your share directly. If your plan charges a flat copay for that tier, your copay may not change at all. Either way, your total Part D out-of-pocket is capped at $2,100 in 2026, after which covered drugs cost you nothing for the rest of the year.

Does insurance cover Entresto?

Generally yes. Entresto is covered by Medicare Part D and most commercial plans, though plans commonly require prior authorization and sometimes step therapy, meaning you try a cheaper option first. The tier it sits on, not whether it is covered, is usually what decides your cost, and the same drug can sit on different tiers in two plans sold in the same ZIP code. Check your plan's formulary for the tier and any restrictions before you fill it.

Related

Sources

  • CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (maximum fair price and list-price comparison)
  • CMS / Medicare.gov (Part D out-of-pocket cap, $2,100 in 2026, and the $615 maximum deductible)
  • FDA Orange Book and Purple Book (approval and substitutability status for sacubitril and valsartan)
  • Novartis published list price and patient-support program terms

Prices are national figures for a 30-day supply at a common dose and vary by pharmacy, dose, and plan. List prices are the figures CMS published as its negotiation comparison. This page is educational and is not medical or financial advice: do not start, stop, or switch a prescription on the basis of price without talking to your prescriber. Last updated November 20, 2026.